Table 2.
Characteristics of the study population by HIV and HCV antibody status
| Median (IQR) or % | HIV−/HCV+ (n=77) |
HIV+/HCV+ (n=248) |
HIV+/HCV− (n=868) |
HIV−/HCV− (n=383) |
P value |
| Sociodemographic | |||||
| Age (years) | 56 (49, 60) | 56 (53, 60) | 49 (43, 54) | 47 (41, 54) | <0.001 |
| Race/Ethnicity | 0.001 | ||||
| Black | 64% | 67% | 76% | 76% | |
| White | 7% | 15% | 9% | 7% | |
| Hispanic | 22% | 17% | 11% | 12% | |
| Other | 7% | 2% | 4% | 5% | |
| Menopause stage | <0.001 | ||||
| Premenopause | 16% | 7% | 33% | 44% | |
| Perimenopause | 13% | 8% | 14% | 14% | |
| Postmenopause | 71% | 85% | 53% | 43% | |
| Household income (US$) | |||||
| <6000 | 29% | 16% | 12% | 19% | <0.001 |
| 6000–12 000 | 44% | 49% | 35% | 26% | |
| 12 001–36 000 | 7% | 13% | 15% | 13% | |
| >36 000 | 9% | 9% | 17% | 23% | |
| Education | |||||
| Less than high school | 43% | 39% | 31% | 32% | 0.02 |
| High school | 35% | 29% | 34% | 28% | |
| More than high school | 22% | 32% | 35% | 41% | |
| Lifestyle | |||||
| Alcohol use | <0.001 | ||||
| None | 51% | 63% | 51% | 42% | |
| Light | 27% | 25% | 40% | 42% | |
| Moderate | 4% | 3% | 3% | 4% | |
| Heavy | 18% | 8% | 6% | 12% | |
| Current smoking | 71% | 54% | 35% | 42% | <0.001 |
| Current marijuana use | 30% | 26% | 20% | 27% | 0.05 |
| Ever injection drug use | 36% | 23% | 1% | 4% | <0.001 |
| Metabolic | |||||
| BMI (kg/m2) | 30 (25, 36) | 28 (23, 32) | 31 (26, 36) | 32 (27, 38) | <0.001 |
| Waist circumference (cm) | 99 (88, 115) | 97 (86, 108) | 99 (89, 111) | 100 (88, 113) | 0.12 |
| HOMA-IR | 3.2 (1.6, 6.8) | 2.48 (1.3, 4.9) | 2.1 (1.3, 3.8) | 1.8 (1.1, 3.3) | <0.001 |
| Liver-related | |||||
| AST (U/L) | 26 (19, 37) | 24 (18, 35) | 19 (15, 23) | 17 (14, 20) | <0.001 |
| ALT (U/L) | 23 (15, 34) | 18 (12, 30) | 15 (12, 21) | 14 (11, 18) | <0.001 |
| HIV-related | |||||
| Undetectable HIV RNA | 69% | 72% | 0.60 | ||
| CD4 current (cells/mm3) | 616 (428, 869) | 656 (435, 870) | 0.35 | ||
| CD4 nadir (cells/mm3) | 215 (107, 320) | 222 (103, 361) | 0.95 | ||
| History of clinical AIDS | 42% | 28% | <0.001 | ||
| Current ART | 89% | 89% | 0.81 | ||
| NNRTI | 30% | 29% | 0.84 | ||
| PI | 26% | 25% | 0.80 | ||
| INSTI | 44% | 48% | 0.22 | ||
| EI | 1.6% | 0.8% | 0.26 |
ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; EI, entry inhibitor; HCV, hepatitis C virus; HOMA-IR, homeostatic model assessment of insulin resistance; INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.